Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease

Simple item page
dc.contributor.authorYılmaz, Yusuf
dc.contributor.authorYönal, Oya
dc.contributor.authorKurt, Ramazan
dc.contributor.authorAktaş, Bilge
dc.contributor.authorÖzdoğan, Osman
dc.contributor.buuauthorBayrak, Muharrem
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı.tr_TR
dc.contributor.scopusid57211333268tr_TR
dc.date.accessioned2021-11-12T07:01:12Z
dc.date.available2021-11-12T07:01:12Z
dc.date.issued2011-02
dc.description.abstractBackground: The aspartate aminotransferases (AST) to platelet ratio index (APRI) may serve as a noninvasive marker to assess liver fibrosis. Objectives: To assess the diagnostic ability of the APRI for prediction of fibrosis in patients with chronic hepatitis B (CHB), chronic hepatitis C (CHC), and non-alcoholic fatty liver disease (NAFLD). Patients and Methods: This retrospective study included 207 patients with CHB,108 with CHC, and 140 patients with NAFLD. The APRI was calculated as (AST level/upper normal limit for AST)/platelet counts (109/L) x 100. The stage of liver fibrosis in patients with chronic viral hepatitis was graded using the METAVIR scale. The Kleiner system for grading fibrosis was used in patients with NAFLD. Results: Bivariate correlation analyses showed that the APRI was significantly associated with fibrosis scores in patients with CHC (p = 0.2634, p = 0.0059) and NAFLD (p = 0.2273, p = 0.0069), but not in those with CHB (p = 0.1005, p = 0.1495). Receiver operating characteristic (ROC) curves were used for assessing the ability of the APRI as a predictor of the absence or presence of liver fibrosis (fibrosis score of 0 vs fibrosis scores of 1-4). In patients with CHC, the APRI showed a sensitivity of 72.7% and a specificity of 62.4% for detection of fibrosis (p<0.01). In the NAFLD group, the APRI showed a sensitivity of 60.0% and specificity of 73.3% for detection of fibrosis (p<0.01). In patients with CHB, the APRI showed a sensitivity of 55.0% and a specificity of 75.4% for fibrosis (p=NS). Conclusions: The APRI shows an acceptable accuracy for the assessment of liver fibrosis in patients with CHC and NAFLD, but not in those with CHB.en_US
dc.identifier.citationYilmaz, Y. vd. (2011). " Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease ". Hepatitis Monthly, 11(2), 103-107.en_US
dc.identifier.endpage107tr_TR
dc.identifier.issn1735-143X
dc.identifier.issue2tr_TR
dc.identifier.pubmed22087126tr_TR
dc.identifier.scopus2-s2.0-79952479754tr_TR
dc.identifier.startpage103tr_TR
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206675/
dc.identifier.urihttp://hdl.handle.net/11452/22628
dc.identifier.volume11tr_TR
dc.identifier.wos000288485300008tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherKowsaren_US
dc.relation.collaborationYurt içitr_TR
dc.relation.journalHepatitis Monthlyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGastroenterology & hepatologyen_US
dc.subjectChronic hepatitis Cen_US
dc.subjectChronic hepatitis Ben_US
dc.subjectFatty liveren_US
dc.subjectFibrosisen_US
dc.subjectAspartate aminotransferasesen_US
dc.subjectChronic hepatitis-cen_US
dc.subjectBlood-testsen_US
dc.subjectPredicten_US
dc.subjectCirrhosisen_US
dc.subjectBiopsyen_US
dc.subjectFibroscan(r)en_US
dc.subjectCoinfectionen_US
dc.subjectValidationen_US
dc.subjectInfectionen_US
dc.subjectDiagnosisen_US
dc.subject.emtreeAspartate aminotransferaseen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeAspartate aminotransferase blood levelen_US
dc.subject.emtreeAspartate aminotransferase to platelet ratio indexen_US
dc.subject.emtreeBivariate analysisen_US
dc.subject.emtreeChronic liver diseaseen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDiagnostic accuracyen_US
dc.subject.emtreeDiagnostic test accuracy studyen_US
dc.subject.emtreeDiagnostic valueen_US
dc.subject.emtreeDisease associationen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHepatitis Ben_US
dc.subject.emtreeHepatitis Cen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeLiver fibrosisen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeNon invasive procedureen_US
dc.subject.emtreeNonalcoholic fatty liveren_US
dc.subject.emtreeReceiver operating characteristicen_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.emtreeSensitivity and specificityen_US
dc.subject.emtreeThrombocyte counten_US
dc.subject.scopusElasticity Imaging Techniques; Esophagus Varices; Chronic Hepatitis Ben_US
dc.subject.wosGastroenterology & hepatologyen_US
dc.titleNoninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver diseaseen_US
dc.typeArticle
dc.wos.quartileQ3en_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
MuharremBayrak_vd_2011.pdf
Size:
797.71 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus